Litcius/Paper detail

Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3

Hope S. Rugo, Jens Huober, José Á. García-Sáenz, Norikazu Masuda, Joohyuk Sohn, Valérie André, Susana Barriga, Joanne Cox, Matthew P. Goetz

2021The Oncologist30 citationsDOIOpen Access PDF

Abstract

The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.

Topics & Concepts

MedicineNeutropeniaAdverse effectInternal medicinePneumonitisToxicityDiarrheaBreast cancerGastroenterologyOncologyCancerSurgeryLungAdvanced Breast Cancer TherapiesNeuroendocrine Tumor Research AdvancesLung Cancer Research Studies
Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3 | Litcius